U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Primary prostate urothelial carcinoma

MedGen UID:
271382
•Concept ID:
C1514430
•
Neoplastic Process
Synonyms: primary prostate urothelial cancer; Primary Prostate Urothelial Carcinoma; primary prostate urothelial carcinoma; prostate gland transitional cell carcinoma; Prostate Transitional Cell Carcinoma; prostate transitional cell carcinoma; Prostate Urothelial Carcinoma; prostate urothelial carcinoma; Transitional Cell Carcinoma of Prostate; transitional cell carcinoma of prostate; Transitional Cell Carcinoma of the Prostate; transitional cell carcinoma of the prostate
 
Monarch Initiative: MONDO:0002834

Definition

An urothelial carcinoma that arises from the urothelial lining of the prostatic ducts or the prostatic urethra. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVPrimary prostate urothelial carcinoma

Professional guidelines

PubMed

Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Guzzo T, Herr HW, Hoffman-Censits J, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wright JL, Gurski LA, Johnson-Chilla A
J Natl Compr Canc Netw 2020 Mar;18(3):329-354. doi: 10.6004/jnccn.2020.0011. PMID: 32135513
Beyond Prostate Adenocarcinoma: Expanding the Differential Diagnosis in Prostate Pathologic Conditions.
Li Y, Mongan J, Behr SC, Sud S, Coakley FV, Simko J, Westphalen AC
Radiographics 2016 Jul-Aug;36(4):1055-75. Epub 2016 Jun 17 doi: 10.1148/rg.2016150226. PMID: 27315446
Differential Diagnosis of Intraductal Lesions of the Prostate.
Wobker SE, Epstein JI
Am J Surg Pathol 2016 Jun;40(6):e67-82. doi: 10.1097/PAS.0000000000000609. PMID: 26848801

Curated

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Bladder Cancer, 2024

Recent clinical studies

Etiology

Predictive and prognostic biomarkers in urological tumours.
Cimadamore A, Franzese C, Di Loreto C, Blanca A, Lopez-Beltran A, Crestani A, Giannarini G, Tan PH, Carneiro BA, El-Deiry WS, Montironi R, Cheng L
Pathology 2024 Mar;56(2):228-238. Epub 2023 Dec 14 doi: 10.1016/j.pathol.2023.10.016. PMID: 38199927
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.
McGregor BA, Sonpavde GP, Kwak L, Regan MM, Gao X, Hvidsten H, Mantia CM, Wei XX, Berchuck JE, Berg SA, Ravi PK, Michaelson MD, Choueiri TK, Bellmunt J
Ann Oncol 2024 Jan;35(1):91-97. Epub 2023 Oct 21 doi: 10.1016/j.annonc.2023.09.3114. PMID: 37871703
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
Yu EY, Petrylak DP, O'Donnell PH, Lee JL, van der Heijden MS, Loriot Y, Stein MN, Necchi A, Kojima T, Harrison MR, Hoon Park S, Quinn DI, Heath EI, Rosenberg JE, Steinberg J, Liang SY, Trowbridge J, Campbell M, McGregor B, Balar AV
Lancet Oncol 2021 Jun;22(6):872-882. Epub 2021 May 12 doi: 10.1016/S1470-2045(21)00094-2. PMID: 33991512
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.
Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J Jr, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL Jr, Sankin AI, Boyd A, O'Donnell MA, Sawutz D, Philipson R, Coll R, Narayan VM, Treasure FP, Yla-Herttuala S, Parker NR, Dinney CPN
Lancet Oncol 2021 Jan;22(1):107-117. Epub 2020 Nov 27 doi: 10.1016/S1470-2045(20)30540-4. PMID: 33253641Free PMC Article
Histologic classification of prostate cancer.
Mikuz G
Anal Quant Cytopathol Histpathol 2015 Feb;37(1):39-47. PMID: 26072633

Diagnosis

Predictive and prognostic biomarkers in urological tumours.
Cimadamore A, Franzese C, Di Loreto C, Blanca A, Lopez-Beltran A, Crestani A, Giannarini G, Tan PH, Carneiro BA, El-Deiry WS, Montironi R, Cheng L
Pathology 2024 Mar;56(2):228-238. Epub 2023 Dec 14 doi: 10.1016/j.pathol.2023.10.016. PMID: 38199927
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022.
Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA
J Natl Compr Canc Netw 2022 Aug;20(8):866-878. doi: 10.6004/jnccn.2022.0041. PMID: 35948037
Immunohistochemical Pitfalls in Genitourinary Pathology: 2018 Update.
Cox RM, Magi-Galluzzi C, McKenney JK
Adv Anat Pathol 2018 Nov;25(6):387-399. doi: 10.1097/PAP.0000000000000205. PMID: 30157041
Urologic cancer in Indonesia.
Umbas R, Safriadi F, Mochtar CA, Djatisoesanto W, Hamid AR
Jpn J Clin Oncol 2015 Aug;45(8):708-12. Epub 2015 Jun 16 doi: 10.1093/jjco/hyv066. PMID: 26085688
GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors.
Miettinen M, McCue PA, Sarlomo-Rikala M, Rys J, Czapiewski P, Wazny K, Langfort R, Waloszczyk P, Biernat W, Lasota J, Wang Z
Am J Surg Pathol 2014 Jan;38(1):13-22. doi: 10.1097/PAS.0b013e3182a0218f. PMID: 24145643Free PMC Article

Therapy

The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.
McGregor BA, Sonpavde GP, Kwak L, Regan MM, Gao X, Hvidsten H, Mantia CM, Wei XX, Berchuck JE, Berg SA, Ravi PK, Michaelson MD, Choueiri TK, Bellmunt J
Ann Oncol 2024 Jan;35(1):91-97. Epub 2023 Oct 21 doi: 10.1016/j.annonc.2023.09.3114. PMID: 37871703
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
Yu EY, Petrylak DP, O'Donnell PH, Lee JL, van der Heijden MS, Loriot Y, Stein MN, Necchi A, Kojima T, Harrison MR, Hoon Park S, Quinn DI, Heath EI, Rosenberg JE, Steinberg J, Liang SY, Trowbridge J, Campbell M, McGregor B, Balar AV
Lancet Oncol 2021 Jun;22(6):872-882. Epub 2021 May 12 doi: 10.1016/S1470-2045(21)00094-2. PMID: 33991512
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.
Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J Jr, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL Jr, Sankin AI, Boyd A, O'Donnell MA, Sawutz D, Philipson R, Coll R, Narayan VM, Treasure FP, Yla-Herttuala S, Parker NR, Dinney CPN
Lancet Oncol 2021 Jan;22(1):107-117. Epub 2020 Nov 27 doi: 10.1016/S1470-2045(20)30540-4. PMID: 33253641Free PMC Article
Urologic cancer in Indonesia.
Umbas R, Safriadi F, Mochtar CA, Djatisoesanto W, Hamid AR
Jpn J Clin Oncol 2015 Aug;45(8):708-12. Epub 2015 Jun 16 doi: 10.1093/jjco/hyv066. PMID: 26085688
Urothelial carcinoma in the prostatic urethra and prostate: current controversies.
Liedberg F, Chebil G, Månsson W
Expert Rev Anticancer Ther 2007 Mar;7(3):383-90. doi: 10.1586/14737140.7.3.383. PMID: 17338657

Prognosis

Predictive and prognostic biomarkers in urological tumours.
Cimadamore A, Franzese C, Di Loreto C, Blanca A, Lopez-Beltran A, Crestani A, Giannarini G, Tan PH, Carneiro BA, El-Deiry WS, Montironi R, Cheng L
Pathology 2024 Mar;56(2):228-238. Epub 2023 Dec 14 doi: 10.1016/j.pathol.2023.10.016. PMID: 38199927
Mucinous and secondary tumors of the prostate.
Osunkoya AO
Mod Pathol 2018 Jan;31(S1):S80-S95. doi: 10.1038/modpathol.2017.132. PMID: 29297488
Urologic cancer in Indonesia.
Umbas R, Safriadi F, Mochtar CA, Djatisoesanto W, Hamid AR
Jpn J Clin Oncol 2015 Aug;45(8):708-12. Epub 2015 Jun 16 doi: 10.1093/jjco/hyv066. PMID: 26085688
Histologic classification of prostate cancer.
Mikuz G
Anal Quant Cytopathol Histpathol 2015 Feb;37(1):39-47. PMID: 26072633
GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors.
Miettinen M, McCue PA, Sarlomo-Rikala M, Rys J, Czapiewski P, Wazny K, Langfort R, Waloszczyk P, Biernat W, Lasota J, Wang Z
Am J Surg Pathol 2014 Jan;38(1):13-22. doi: 10.1097/PAS.0b013e3182a0218f. PMID: 24145643Free PMC Article

Clinical prediction guides

Predictive and prognostic biomarkers in urological tumours.
Cimadamore A, Franzese C, Di Loreto C, Blanca A, Lopez-Beltran A, Crestani A, Giannarini G, Tan PH, Carneiro BA, El-Deiry WS, Montironi R, Cheng L
Pathology 2024 Mar;56(2):228-238. Epub 2023 Dec 14 doi: 10.1016/j.pathol.2023.10.016. PMID: 38199927
Impact of smoking on urologic cancers: a snapshot of current evidence.
Kumar R, Matulewicz R, Mari A, Moschini M, Ghodoussipour S, Pradere B, Rink M, Autorino R, Desai MM, Gill I, Cacciamani GE
World J Urol 2023 Jun;41(6):1473-1479. Epub 2023 Apr 24 doi: 10.1007/s00345-023-04406-y. PMID: 37093319Free PMC Article
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
Yu EY, Petrylak DP, O'Donnell PH, Lee JL, van der Heijden MS, Loriot Y, Stein MN, Necchi A, Kojima T, Harrison MR, Hoon Park S, Quinn DI, Heath EI, Rosenberg JE, Steinberg J, Liang SY, Trowbridge J, Campbell M, McGregor B, Balar AV
Lancet Oncol 2021 Jun;22(6):872-882. Epub 2021 May 12 doi: 10.1016/S1470-2045(21)00094-2. PMID: 33991512
Histologic classification of prostate cancer.
Mikuz G
Anal Quant Cytopathol Histpathol 2015 Feb;37(1):39-47. PMID: 26072633
GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors.
Miettinen M, McCue PA, Sarlomo-Rikala M, Rys J, Czapiewski P, Wazny K, Langfort R, Waloszczyk P, Biernat W, Lasota J, Wang Z
Am J Surg Pathol 2014 Jan;38(1):13-22. doi: 10.1097/PAS.0b013e3182a0218f. PMID: 24145643Free PMC Article

Recent systematic reviews

Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma Working Group.
Laukhtina E, Moschini M, Soria F, Andrea DD, Teoh JY, Mori K, Albisinni S, Mari A, Krajewski W, Cimadamore A, Abufaraj M, Enikeev D, Neuzillet Y, Giannarini G, Xylinas E, Kamat AM, Roupret M, Babjuk M, Witjes JA, Shariat SF, Pradere B; European Association of Urology; Young Academic Urologists EAU-YAU: Urothelial Carcinoma Working Group; European Association of Urology Section of Oncological Urology ESOU
Eur Urol Focus 2022 Nov;8(6):1635-1642. Epub 2022 Mar 23 doi: 10.1016/j.euf.2022.03.004. PMID: 35337773
Sarcopenic Obesity and its Prognostic Impact on Urological Cancers: A Systematic Review.
Stangl-Kremser J, Mari A, Lai LY, Lee CT, Vince R, Zaslavsky A, Salami SS, Fajkovic H, Shariat SF, Palapattu GS
J Urol 2021 Oct;206(4):854-865. Epub 2021 May 25 doi: 10.1097/JU.0000000000001873. PMID: 34032495
Quality Indicators for Bladder Cancer Services: A Collaborative Review.
Leow JJ, Catto JWF, Efstathiou JA, Gore JL, Hussein AA, Shariat SF, Smith AB, Weizer AZ, Wirth M, Witjes JA, Trinh QD
Eur Urol 2020 Jul;78(1):43-59. Epub 2019 Sep 26 doi: 10.1016/j.eururo.2019.09.001. PMID: 31563501
Current Disease Management of Primary Urethral Carcinoma.
Janisch F, Abufaraj M, Fajkovic H, Kimura S, Iwata T, Nyirady P, Rink M, Shariat SF
Eur Urol Focus 2019 Sep;5(5):722-734. Epub 2019 Jul 13 doi: 10.1016/j.euf.2019.07.001. PMID: 31307949
Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy.
Gakis G, Black PC, Bochner BH, Boorjian SA, Stenzl A, Thalmann GN, Kassouf W
Eur Urol 2017 Apr;71(4):545-557. Epub 2016 Oct 6 doi: 10.1016/j.eururo.2016.09.035. PMID: 27720534Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Curated

    • NCCN, 2024
      NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Bladder Cancer, 2024

    Consumer resources

    Reviews

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...